Connect Biopharma is trading 7.2% up now at $2.38 following renewed analyst optimism and ongoing interest in its inflammatory disease pipeline. - Oppenheimer initiated coverage with an Outperform rating and an $8.00 price target today, while H.C. Wainwright reiterated a Buy rating with a $7.00 price target. - Sentiment is bolstered by upcoming rademikibart trial milestones, including anticipated topline data from Phase 2 Seabreeze STAT asthma and COPD studies in early September 2026 and mid-2026 respectively, and the company's strategic priorities.